Felix C Popp
Overview
Explore the profile of Felix C Popp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
576
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grothey B, Lyu S, Quaas A, Simon A, Jung J, Schroder W, et al.
Cell Mol Life Sci
. 2025 Mar;
82(1):112.
PMID: 40074836
Background: Esophageal adenocarcinomas (EACs) represent an evolving tumor entity with high mortality rates. MET amplification is a recurrent driver in EACs and is associated with decreased patient survival. However, the...
2.
Knipper K, Lyu S, Jung J, Alich N, Popp F, Schroder W, et al.
Sci Rep
. 2024 Sep;
14(1):20589.
PMID: 39232098
In esophageal adenocarcinoma, the presence of lymph node metastases predicts patients' survival even after curative resection. Currently, there is no highly accurate marker for detecting the presence of lymph node...
3.
Lyu S, Fretter C, Simon A, Spielmann S, Damanakis A, Zhao Y, et al.
Transl Oncol
. 2024 Jun;
47:102044.
PMID: 38917592
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is associated with poor prognosis, wherefore targeted therapies have experienced increasing interest. Zolbetuximab is a novel targeted therapy under investigation in patients with PDAC and...
4.
Knipper K, Lemties J, Krey T, Lyu S, Wirsik N, Schiffmann L, et al.
BJS Open
. 2024 May;
8(3).
PMID: 38814750
Background: In contrast to the well-established multimodal therapy for localized oesophageal cancer, the metastatic stage is commonly treated only with systemic therapy as current international guidelines recommend. However, evidence suggesting...
5.
Knipper K, Krey T, Lyu S, Jung J, Wirsik N, Fuchs H, et al.
World J Surg
. 2024 Mar;
48(6):1414-1423.
PMID: 38554145
Purpose: Patients with local recurrence of esophageal cancer have a highly decreased overall survival. There is currently no standardized treatment algorithm for this group. This retrospective cohort study aimed to...
6.
Knipper K, Hussein Y, Simon A, Fretter C, Damanakis A, Zhao Y, et al.
J Cancer Res Clin Oncol
. 2024 Mar;
150(3):137.
PMID: 38502354
Purpose: Patients with pancreatic ductal adenocarcinoma (PDAC) have yet to experience significant benefits from targeted therapy. Olaparib is currently the only active substance in BRCA-mutated PDACs that successfully influences the...
7.
Lyu S, Popp F, Simon A, Schultheis A, Zander T, Fretter C, et al.
Sci Rep
. 2023 Oct;
13(1):17699.
PMID: 37848472
Esophageal adenocarcinoma exhibits one of the highest mortality rates among all cancer entities. Multimodal therapy strategies have improved patients' survival significantly. However, patients in early stages are currently limited to...
8.
Knipper K, Damanakis A, Zhao Y, Bruns C, Schmidt T, Popp F, et al.
Cancers (Basel)
. 2023 Apr;
15(7).
PMID: 37046710
Purpose: The pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancer entities. Effective therapy options are still lacking. The tumor microenvironment possibly bears further treatment possibilities. This study...
9.
Lyu S, Krey T, Damanakis A, Zhao Y, Bruns C, Schmidt T, et al.
J Cancer Res Clin Oncol
. 2023 Mar;
149(10):7539-7546.
PMID: 36971797
Purpose: Rising incidence of pancreatic ductal adenocarcinoma (PDAC) bind with insufficient therapy options showcases a great medical challenge. Further biomarkers are required to identify patients, who will benefit from more...
10.
Pisula J, Datta R, Valdez L, Avemarg J, Jung J, Plum P, et al.
Br J Cancer
. 2023 Jan;
128(7):1369-1376.
PMID: 36717673
Background: Fast and accurate diagnostics are key for personalised medicine. Particularly in cancer, precise diagnosis is a prerequisite for targeted therapies, which can prolong lives. In this work, we focus...